Drug profile · INN
voclosporin
LUVENIQ
voclosporin (LUVENIQ) is a serine/threonine protein phosphatase 2b catalytic subunit, alpha isoform inhibitor. Associated with Aurinia Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — voclosporin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 3
- Programs
- 12
- Data quality
- 0.89
Quick answer
voclosporin (LUVENIQ) is a serine/threonine protein phosphatase 2b catalytic subunit, alpha isoform inhibitor. Associated with Aurinia Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
Primary target: Protein phosphatase 3 catalytic subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is voclosporin?
voclosporin (LUVENIQ) is a serine/threonine protein phosphatase 2b catalytic subunit, alpha isoform inhibitor. Associated with Aurinia Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for voclosporin?
LUVENIQ is a marketed brand name for voclosporin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of voclosporin?
voclosporin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.